ERBB2 and breast cancer: In another phase 2 NSABP FB-7 neoadjuvant trial by Jacobs SA et al., 126 patients with locally advanced HER2-positive BC were randomly divided into 3 groups (1:1:1): Control group with trastuzumab (4 mg/kg loading dose, followed by 2 mg/kg weekly) + paclitaxel (60 mg/m2 weekly) (T + P), experimental group with neratinib (240 mg) + paclitaxel (N + P), and combination group (trastuzumab + neratinib + paclitaxel; T + N + P).